A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

The main purpose of this study is to see how well a new treatment ramantamig‐D workscompared to standard treatments that is either DVRd or DRd on progression‐free survival(PFS; time until a participant's disease worsens) and 12‐month minimal residue disease(MRD)‐negative complete response (CR) rate (percentage of participants in whom cancercells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; aninitial stage of blood cancer that forms in a type of white blood cells [WBCs] calledplasma cells) for whom stem cell transplant is not planned as initial therapy.